Globe Newswire

WESTCHESTER, Ill., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.78 per share on the Company’s common stock. The dividend is payable on July 23, 2024, to stockholders of record at the close of business on July 1, 2024.

About the CompanyIngredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving... (continue reading...)

MENLO PARK, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for April 2024:

• Funded Customers at the end of April were 24.0 million, up approximately 90 thousand from March 2024.
• Assets Under Custody (AUC) at the end of April were $123.3 billion, down 5% from March 2024. Net Deposits were $4.9 billion in April, translating to a 45% annualized growth rate relative to March... (continue reading...)

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.

WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and... (continue reading...)

• On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024
• Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI
• Received FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPA
• Cash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025

CAMBRIDGE, Mass.,... (continue reading...)

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

Recent Highlights

• Announced global commercialization partnership with Bio-Rad Laboratories, Inc.
• On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development... (continue reading...)